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Background/Aims: The chromatin remodeler DAXX, a predominantly nuclear protein, regulates the status of
chromatin organization. The aim of this exploratory immunohistochemical study was to evaluate DAXX protein
expression in high grade invasive urothelial carcinoma (UC) of the bladder as a biological regulator of
aggressiveness.
Methods: Quantitative analysis was made on DAXX immunostained nuclei in tissue sections from 5 cases of
bladder normal urothelium (NU) and 5 cases of bladder pT1 UC. Carcinoma in situ (CIS) and high grade papillary
carcinoma (HGPCa) were identified in 2 out of 5 UC cases.
Results: The nuclei in UC show an open configuration of the chromatin composed of granules varying in size
and distribution and a mean nuclear area 1.7 times greater than that in NU (UC: mean and SD 24.4 ± 11.4 square
microns; NU: 14.8 6.5 square microns. The differences are statistically significant). 70% of the NU nuclei are
immunostained, whereas 90% of UC nuclei are positive. The mean gray level value in UC, related to the intensity
of nuclear immunostaining, is lower than in NU by a factor of 0.94 (UC: mean and SD 100 ± 15; NU: 106 ± 15.
The differences are statistically significant). In particular, the value in the nuclei adjacent to the stroma in UC is
slightly lower than in the intermediate cell layers by factor of 0.98, whereas in NU it is slightly greater by a factor
1.02 and 1.04 compared to the intermediate and superficial cell layers. The values in CIS and HGPCa are similar
to those in UC.
Conclusions: The quantitative immunohistochemical analysis shows an altered protein expression of chromatin
remodeler DAXX in UC and in its preinvasive phases, when compared to NU. DAXX evaluation, if associated with
markers related to global DNA methylation and histone acetylation, could be used in clinical practice as a marker
of aggressiveness.
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Urinary bladder cancer is the fifth most common cancer
in the western world. The relative 5-year survival rate of
≈ 70% has not changed the last few decades [1]. The
clinical presentation of the disease is heterogeneous,
ranging from tumors with low malignant potential to
highly malignant muscle infiltrating tumors [2]. Despite
refined histology-based classification systems, it is difficult
to predict the individual prognosis and response to therapy.
For instance, a third of patients with T1 tumors remain
recurrence-free after BCG treatment, while a third die from
the disease. Therefore clinical biomarkers identifying
aggressive tumors are clearly desirable [3].
Gene-expression signatures associated with different
clinical variables such as cancer progression have been
proposed. One major drawback is that gene-expression
analyses require access to frozen tissue for extraction
of high-quality DNA and RNA. However, in clinical
routine, mainly formalin fixed paraffin-embedded
tissue samples have been preserved and archived. To
retrieve information at protein level from these invaluable
materials, with long and extensive patient follow-up data,
immunohistochemistry is an ideal approach to identify
potential new biomarkers [3].
Several biological regulators of aggressiveness have
been suggested as biomarkers in bladder cancer,
including p53, p21, Rb, FGFR3 and survivin [4-7].
However, results are often inconclusive and the clinical
impact remains poor. Previous immunohistochemical
investigations made by our group showed the status
of chromatin organization, evaluated with global DNA
methylation and histone acetylation analysis, to have
a potential prognostic value in UC [8,9].
The chromatin remodeler DAXX, a predominantly
nuclear protein, often localized within subnuclear
compartments called PML (promyelocytic leukemia
protein) oncogenic domains, regulates the status of
chromatin organization [10-13]. Recent studies on
formalin fixed paraffin-embedded tissue samples have
linked chromatin remodeler DAXX expression with
tumor aggressiveness in cancer patients [14-18].
The aim of this exploratory study was to investigate
quantitatively the immunohistochemical expression of
chromatin remodeler DAXX in T1 high-grade UC of
the bladder as a potential biological regulator of tumor
aggressiveness.
Methods
Patients and tissue samples
The procedure for this research project conforms to
the provisions of the Declaration of Helsinki. The
study included 5 cases of bladder NU obtained from
patients with benign prostatic hyperplasia and no
history of bladder and prostate cancer and 5 cases ofbladder pT1 UC. The material was retrieved from the
Pathology Services associated with Polytechnic University
of the Marche Region-United Hospitals. All the cases had
been fixed in 4% buffered formaldehyde for approximately
24 hours before processing. The hematoxylin- and eosin-
stained sections were retrieved from the archives and
reviewed by one of our team (RM). The original diagnosis
of NU and of invasive UC was confirmed in all the cases.
A small component of CIS and of HGPCa was identified
in 2 out of 5 UC cases.
Immunohistochemistry
Five-micron thick sections were cut from the paraffin
blocks, dewaxed in xylene and rehydrated through a
graded series of ethanol. Antigen retrieval was done by
microwave treatment for 20 min at 98°C using 0.01 M
Citric Acid buffer pH 6.0. Endogenous peroxidase activity
was quenched by incubating the sections in 3% hydrogen
peroxide for 10 min at room temperature. Non-specific
binding sites were blocked through pre-incubation with 5%
normal goat serum in PBS for 10 min at room temperature.
DAXX immunostaining was performed using a polyclonal
antibody (1:100, Sigma). Antigen-antibody complex was
subsequently visualized using the Envision™ Detection
System kit peroxidase/DAB (DAKO, Glustrop, Denmark)
and counterstained with hematoxylin. Negative controls
were used for the tested antibodies; the primary antibody
was replaced by either mouse or rabbit non-immune
serum, as appropriate.
Evaluation of immunohistochemistry
Several images representative of NU, CIS, HGPCa
and UC were recorded with a Nikon digital camera
mounted on a Nikon Eclipse E800 microscope at the
objective magnification of 20×. The nuclear area
(unit of measurement: square microns; calibration was
based on the measurement of nuclei with known diameter)
and the intensity of nuclear staining (unit of measurement:
gray levels) were analyzed with the LabVIEW software
(National Instruments, Austin, Texas). For the NU cases
and in the two cases of CIS and HGPCa associated with
UC the nuclei were separately evaluated in the following
three compartments: cell layer adjacent to the stroma,
i.e., basal cells; superficial or luminal cell layer; and
intermediate cells, i.e., those between the basal cells
and superficial cells. Since superficial cells are not
present in UC, the nuclei were evaluated in the cell
layer adjacent to the stroma, the nuclei in all the
other cell layers being considered equivalent to the
intermediate nuclei of NU. At least 40 nuclei per location
were measured in each case, for a total of 1300 nuclei. For
each nucleus the mean nuclear gray value was calculated
from the gray value of the individual picture elements in
the green color plane. The nuclei were pooled together
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each group and for each location was calculated. This
was due to the fact that the number of cases analyzed
in each group was reactively small. However, an attempt
made to calculate the mean and standard deviation
per each group based on individual cases did not
shown substantial differences with the figures obtained
from the pooled nuclei.
Since the aim of this study was the feasibility of
quantifying DAXX immunostaining as a potential biological
regulator of aggressiveness, statistical analysis was applied
to a limited extent only (Student’s T test; significance at
p< 0.05) and not throughout all the steps the study.Results
Evaluations on hematoxylin- and eosin-stained sections
The nuclei of NU are round to oval. Visually they are
almost two times the size of the nuclei of the small
lymphocytes in the subepithelial connective tissue. The
chromatin is slightly less condensed compared to the
hyperchromatic nuclei of the lymphocytes. The nucleoli
are not visible. Mitotic figures are absent. The nuclei in
UC, at least three times larger than the nuclei of the
lymphocytes, show an open configuration of the
chromatin composed of granules varying in size and
distribution. The nucleoli are prominent and visible
in the majority of nuclei. The CIS and HGPCa
nuclei, including their chromatin distribution, are
morphologically indistinguishable from those in UC.
Mitotic figures are present in all UC cases, including in the
noninvasive CIS and HGPCa components. There is neither
acute nor chronic inflammation other than scattered
lymphocytes randomly distributed in the subepithelial
connective tissue.Qualitative and quantitative valuations on DAXX
immunostained slides
Invasive urothelial carcinoma vs. normal urothelium
Karyometric analysis further defines the nuclear size in
addition to that based on the subjective evaluation on
hematoxylin- and eosin-stained slides. The nuclear size
in UC is 1.7 times greater than that in NU (UC: mean
and SD 24.4 ± 11.4 square microns; NU: 14.8 ± 6.5
square microns. The differences are statistically significant).
The nuclei in the cells adjacent to the stroma in UC and in
the basal cells in NU are slightly smaller than in the
intermediate cells by a factor of 0.96 and 0.86 in the
UC and NU cases, respectively, the difference being
not statistically significant. The mean nuclear area of
the nuclei in the superficial cell layer in NU is identical
to the nuclei in the intermediate cell layers. This
means that the nuclei increase in size when they migrate
from basal or adjacent to the stroma position to theintermediate location, but the size does not change in NU
when the nuclei reach the surface.
The DAXX antibody stains the nuclei in all diagnostic
groups and all nuclear locations (Figures 1 and 2)
(Table 1). In particular, 70% of the NU nuclei are immu-
nostained, whereas 90% of UC nuclei are positive.
The intensity of staining of the positive nuclei ranges
from weak-to-moderate to strong. There is no spatial
association between strong stained nuclei or negative
nuclei and mitoses. Some faint immunostaining is seen in
the cytoplasm of scattered epithelial cells, both in NU,
mostly in the superficial cell layer (Figure 1), and UC.
Nonepithelial cells in the stroma, including smooth muscle
cells and endothelial cells, are not stained. Quantitative
evaluation was done on the epithelial nuclei only.
The mean nuclear gray value in UC is lower than in
NU by a factor of 0.94 (UC: mean and SD 100 ± 15; NU:
106 ± 15. The differences are statistically significant).
The value in the nuclei adjacent to the stroma in UC is
slightly lower than in the intermediate cell layers by
factor of 0.98, whereas in NU it is slightly greater by a
factor 1.02 and 1.04 compared to the intermediate and
superficial cell layers, i.e., the trend of DAXX protein
expression changes in the various nuclear locations in
NU is different from that in UC, being decreasing in the
former and increasing in the latter. This points out that
DAXX protein expression in UC is different from that in
NU in terms of staining intensity and nuclear location.
DAXX staining is not homogeneous within each
individual nucleus. It shows a granular pattern, some
granules being darker than others. An attempt was
made to further characterize the nuclear staining pattern
in UC compared with NU based on the highest gray value
per nucleus. Such an approach does not add information
behind that derived from the mean nuclear gray value per
nucleus (further data not shown).
Carcinoma in situ and high grade urothelial papillary
carcinoma
There are no differences between CIS and HGPCa
concerning nuclear size and mean gray values related to
DAXX immunostaining. Compared to NU, the nuclear
area is greater by a factor of 1.7, as in UC. The trend of
changes in the three nuclear locations is similar to that
in NU, i.e., increasing from the basal position to the
surface. The mean nuclear gray values in CIS and
HGPCa are similar similar to that invasive UC and lower
than in NU, however they retain the pattern of changes
in the nuclear locations seen in NU, i.e., decreasing from
the basal position to the surface.
Discussion
The current study shows two major findings. One is
represented by the significant changes in nuclear size
Figure 1 DAXX immunostaining in normal urothelium. Nuclear staining is present in basal, intermediate and superficial position. Not all the
nuclei are stained. Note that the intensity of immunostaining is not homogeneous throughout the cell layers. The superficial or umbrella cells
show some stating in the cytoplasm in addition to that of the nuclei. (Original microscope objective magnification 20×).
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preinvasive lesions compared with NU. The other is
represented by an altered expression of the chromatin
remodeler DAXX in UC as well as in CIS and HGPCa,
compared with NU. The nuclear size depends on the
DNA content as well as on the status of chromatin
organization. The latter depends on epigenetic events,
such as DNA methylation and histone modifications, and
is regulated by the chromatin remodeler DAXX [10-13].
Compared to normal cells, DNA of cancer cells is
generally hypomethylated, while promoters of certain
genes are hypermethylated, in the context of CpG
islands. Such promoter-specific increase in methylation
leads to silencing of the affected gene that might have
functioned as, for instance, a tumor suppressor. Tran-
scriptional repression by DNA methylation is mediated byFigure 2 DAXX immunostaining in urothelial carcinoma. The majority
homogenous, some nuclei being darker than others. No cytoplasmic stainia class of methyl DNA binding proteins which, by virtue
of recognizing specifically methylated DNA sequences,
recruit repressive protein complexes including histone
deacetylases to gene promoters (see below) [8,9,19]. The
combination of CpG island methylation, proteins that
binds to them, and repressive histone modifications
generates localized regions of specialized chromatin,
which can inhibit transcription. Despite a growing
list of genes including tumor suppressors and DNA
repair genes that are aberrantly hypermethylated in
different cancers, only a limited number of the identified
hypermethylated genes have demonstrated any potential
utility in clinical decision making. As opposed to single-
gene analysis, the integrated information on methylation
patterns of multiple genes may reflect the functional status
of several cellular pathways [19,20].of nuclei are stained at all cell levels. Nuclear staining is not
ng is present. (Original microscope objective magnification 20×).
Table 1 DAXX immunohistochemistry results in normal
urothelium and in urothelial carcinoma
Mean (±SD) nuclear gray level
Normal urothelium (NU), global 106±15
NU, superficial epithelial layer 104±15
NU, intermediate cell layers 106±15
NU, basal cell layer 108±14
Urothelial carcinoma (UC), global 100±15
UC, nuclei not adjacent to the stroma 101±15
UC, nuclei adjacent to the stroma 99±16
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histochemical approach was adopted by our group
using a monoclonal antibody that recognize the
presence of a methyl group on the carbon 5 of cytosine.
This allowed the analysis of global methylation to be
performed on interphase nuclei, on a cell by cell basis
by microscopy [20]. Negative nuclei and those with
weak-to-moderate intensity were considered unmethylated
and hypomethylated, respectively, whereas those strongly
stained as hypermethylated. That study showed an altered
global DNA methylation pattern in UC compared
with NU, the proportion of nuclei with weak-to-moderate
intensity in the former being greater than that of strongly
stained. This was interpreted as an increased global DNA
unmethylation and hypomethylation in UC compared
with NU [8,9].
Histones are subject to a variety of post-translational
modifications, including acetylation of lysines. Such
modifications play fundamental roles in gene regulation
and other chromatin-based processes. Histone-modifying
enzymes affect histones either locally, through targeted
recruitment by sequence specific transcription factors
[21], or globally throughout the genome in an untargeted
manner, affecting virtually all nucleosomes [22]. Such
widespread functions that occur independently of
apparent sequence-specific DNA binding proteins are
referred to as global histone modifications. Like their
targeted effects, the global activity of the histone modifying
enzymes can modulate gene activity [22]. Therefore,
histones are modified locally and globally through
multiple histone-modifying enzymes with different
substrate specificities, generating hierarchical patterns
of modifications from single promoters to large regions of
chromosomes and even single cells.
Since histone modifications occur throughout the
genome, any potential change in the activity of the
histone modifying enzymes results in changes in
specific histone patterns detectable at the level of
individual nuclei by immunohistochemistry. While
the immunohistochemical approach provides infor-
mation on global histone acetylation, it does not giveinformation on the genomic, gene–gene differences
in distribution of histone modifications. To investi-
gate global histone acetylation in UC an immunohis-
tochemical approach was previously adopted by our
group using a polyclonal antibody raised against
acetylated H3K9 (i.e., lysine 9 (K9) of histone 3)
[8,9]. The study showed an altered pattern of global
histone acetylation in UC, the percentages of positive
nuclei being higher than in NU.
These two previous investigations pointed out that
the chromatin pattern in UC is associated with an
increased global DNA unmethylation and hypomethylation
and with an altered pattern of global histone acetylation
compared with NU [8,9]. The current study, performed on
the same series of cases, indicates that such changes
in UC are associated with an increased number of
DAXX positive nuclei whose intensity of nuclear
immunostaining is lower than in NU by a factor of
0.94. Since DAXX is a repressor of gene expression
that binds DNA methyl transferases, histone deacetyl
transferases and chromatin-modifying proteins, the
findings in the current study are of paramount importance
to explain the changes in DNA methylation and histone
acetylation in UC.
There is only one previous study by Segersten et al. [3]
on DAXX immunohistochemistry in bladder neoplasms.
The investigation was performed on tissue microarray
(TMA) material comprising a range of noninvasive
and invasive bladder cancer. The aim was to screen a
publicly available immunohistochemistry based web-
atlas to identify key proteins that might serve as
potential biomarkers. The study did not focus on
DAXX, as in our study, but involved a series of
proteins. The expression of ALCAM, CN130, DAXX,
GAL1, PHF6 and XPA were significantly correlated
with tumor grade and stage. ALCAM and GAL1
expression were increased with advanced stage, whilst
the others were decreased. In particular, GAL1
expression was higher in poorly differentiated tumors,
whilst DSG3 and DAXX protein expression was
decreased. Our current study confirms Segersten et
al’s findings of a decreased DAXX protein expression
in UC and expands our knowledge in this field
because it shows that its altered expression correlates
with previously observed changes in DNA methylation
and histone acetylation.
In conclusion, the quantitative immunohistochemical
analysis shows an altered expression of chromatin
remodeler DAXX in UC and in its preinvasive
phases, when compared with NU. In particular, the
evaluation of the DAXX protein expression, if associated
with other markers related to global DNA methylation
and histone acetylation, could be used in clinical practice
as a marker of aggressiveness.
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